TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Distal Bifurcation Angle (BA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Lesion Revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients in compliance with all applicable SOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of visits for which care was indicated and residents provided proper care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scar pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with eGFR<60 ml/min/1.73 m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: quality of residual erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean period between admission and operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative ileus duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mood symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gain in Bishop score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment-induction to delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failed management rate
Endpoint domain: Adverse events/effects
Primary endpoint: Psychological scoring
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FD symptoms scoring
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone Mineral Density (BMD) at the spine and whole body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Urinary hydroxyproline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum osteocalcin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of recurrences of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of chronic intestinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: diurnal cortisol secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CAT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deviations from laboratory reference range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical status deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total procedural time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of traditional cystoscopy equipment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Differentially expressed proteins in sera
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: throat soreness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sore throat relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional impairment scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MUC5AC mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MUC5AC protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antihypertensive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caries rate per 100 surface-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of acne scars at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tooth shade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RERs of death
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduction in cutaneous erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction in telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction in patient-reported associated symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in mean frequency of binge-eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission from binge-eating and compensatory behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attenuation of bronchial hyperresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: adenosine monophosphate (AMP) improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: methacholine improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean central venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean pulmonary artery occlusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluid responsiveness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lutein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean rate of serum CEA level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum titer of anti‐idiotypic IgG antibodies to SK‐1 (Ab2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: illness self-management
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Triglycerides (Tg) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean number of coughs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Final systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of acceptably treated asthma patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of acceptably treated urinary tract infection patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold increase in antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expanded Prostate Cancer Index‐Short Form urinary scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function in memory, attention, and executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lung cancer detection rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of circulating CD34+ HPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of circulating EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of circulating CECs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thallium uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contractile response to low-dose dobutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SFMPQ2 score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Total IPSS increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAPS after ureteral stent insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of gross hematuria
Endpoint domain: Adverse events/effects
Primary endpoint: core symptoms of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waking SaO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of time spent at SaO(2) below 80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sleep efficiency index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion needing regrafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Partial graft loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: interface stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of motion (ROM) of C4-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-disc stress and facet loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in PWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive rates of bacterial culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: neurological complications (stroke and transient ischemic attack)
Endpoint domain: Adverse events/effects
Primary endpoint: ischemia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: life-years free of stroke or myocardial infarction (MI) gained
Endpoint domain: Mortality/survival
Primary endpoint: life-years free from major bleeding lost
Endpoint domain: Mortality/survival
Primary endpoint: Postintervention multiple-choice test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived depth of learning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enjoyment of CBL delivery method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to delivery of endovascular therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported usual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrient intake levels (folate, fiber, iron, thiamin, riboflavin, omega-3 fatty acids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of metachronous cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adjusted fibrinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: initial symptomatic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrences of depressive illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 25(OH)D at 34 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sunscreen application thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric Inventory total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum interleukin‐18 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble interleukin‐2 receptor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of natural killer (NK) cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apparent clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent volume of distribution (V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of the absorbed dose (F3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dystonia severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brush-evoked pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ongoing pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause, diarrhea, and pneumonia hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Circulating endothelial cell (CEC) numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of apoptotic human endothelial cells (hEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overactive bladder-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relief of bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Association with neovascular AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug pickup adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum NO levels in joint cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential waist reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for e-MiniAQLQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion time for e-MiniAQLQ
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum uric acid reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency of the MTHFR C677T mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time of intragastric pH >6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Grade 3-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cesarean rates
Endpoint domain: Adverse events/effects
Primary endpoint: Nicotine intake (plasma cotinine concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary NNAL excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Karnofsky score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (MOS-HIV)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of resistin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall experience with e-Consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for paper consent
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: major CHD events
Endpoint domain: Mortality/survival
Primary endpoint: heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Child emotional knowledge
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in child behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FMD area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence rate of moderate or severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forward displacement of the zygomaxillary complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improvement in SNA and ANB angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency water stockpiling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Food stockpiling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Family communication plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Labeling efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to follow-up eye care
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: change in reflection magnitude (RM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety levels in providing IUD services
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of comfort in providing IUD services
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total duration of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to full recovery
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Length of sick leave
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frequency and intensity of abdominal pain episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of pain relieving drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of child school and adult work absences
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean change in square root of RT area (RTdd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in area of HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the degree to which RT involved or threatened the center of the macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler embolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-rated goal attainment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-rated satisfaction with goal attainment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: school enrollment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reduced functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Surgical site infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Successful outcome of indirect pulp treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melatonin plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rhythmicity of melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Grade 3 or more neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: indices of the aerobic exercise group and Acu-TENS group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of intestinal protozoa infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes